Zur Kurzanzeige

dc.contributor.authorVelasco Tirado, Virginia 
dc.contributor.authorAlonso Sardón, Montserrat 
dc.contributor.authorLópez Bernús, Amparo 
dc.contributor.authorRomero-Alegría, Ángela
dc.contributor.authorBurguillo Muñoz, Francisco Javier 
dc.contributor.authorMuro Álvarez, Antonio 
dc.contributor.authorCarpio Pérez, Adela 
dc.contributor.authorMuñoz Bellido, Juan Luis 
dc.contributor.authorPardo-Lledias, Javier
dc.contributor.authorCordero, Miguel
dc.contributor.authorBelhassen García, Moncef 
dc.date.accessioned2025-01-31T11:49:19Z
dc.date.available2025-01-31T11:49:19Z
dc.date.issued2018-07-05
dc.identifier.citationVelasco-Tirado V, Alonso-Sardón M, Lopez-Bernus A, Romero-Alegría Á, Burguillo FJ, Muro A, Carpio-Pérez A, Muñoz Bellido JL, Pardo-Lledias J, Cordero M, Belhassen-García M. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis. 2018 Jul 5;18(1):306. doi: 10.1186/s12879-018-3201-yes_ES
dc.identifier.urihttp://hdl.handle.net/10366/163276
dc.description.abstract[EN] Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical treatment of CE. A thorough electronic search of the relevant literature without language restrictions was carried out using PubMed (Medline), Cochrane Central Register of Controlled Trials, BioMed, Database of Abstracts of Reviews of Effects, and Cochrane Plus databases up to February 1, 2017. All descriptive studies reporting an assessment of CE treatment and published in a peer-reviewed journal with available full-text were considered for a qualitative analysis. Randomized controlled trials were included in a quantitative meta-analysis. We used the standard methodological procedures established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We included 33 studies related to the pharmacological treatment of CE in humans. Of these, 22 studies with levels of evidence 2 to 4 were qualitatively analysed, and 11 randomized controlled trials were quantitatively analysed by meta-analysis. Treatment outcomes are better when surgery or PAIR (Puncture, Aspiration, Injection of protoscolicidal agent and Reaspiration) is combined with benzimidazole drugs given pre- and/or post-operation. Albendazole chemotherapy was found to be the primary pharmacological treatment to consider in the medical management of CE. Nevertheless, combined treatment with albendazole plus praziquantel resulted in higher scolicidal and anti-cyst activity and was more likely to result in cure or improvement relative to albendazole alone.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEchinococcus granulosus
dc.subjectCystic echinococcosis
dc.subjectAlbendazole
dc.subjectMebendazole
dc.subjectPraziquantel
dc.subject.meshNeglected Diseases *
dc.subject.meshHumans *
dc.subject.meshDrug Therapy *
dc.subject.meshAlbendazole *
dc.subject.meshAnthelmintics *
dc.subject.meshEchinococcosis *
dc.subject.meshPraziquantel *
dc.subject.meshBenzimidazoles *
dc.titleMedical treatment of cystic echinococcosis: systematic review and meta-analysis.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1186/s12879-018-3201-yes_ES
dc.subject.unesco3205.05 Enfermedades Infecciosas
dc.identifier.doi10.1186/s12879-018-3201-y
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid29976137
dc.identifier.essn1471-2334
dc.journal.titleBMC infectious diseaseses_ES
dc.volume.number18es_ES
dc.issue.number1es_ES
dc.page.initial306es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsequinococosis *
dc.subject.decsenfermedades desatendidas *
dc.subject.decshumanos *
dc.subject.decsantihelmínticos *
dc.subject.decsbencimidazoles *
dc.subject.decspraziquantel *
dc.subject.decsalbendazol *
dc.subject.decsfarmacoterapia *


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional